Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Nivolumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 130 Carcinoma, Non-Small-Cell Lung 95 Carcinoma, Renal Cell 66 Neoplasm Metastasis 49 Carcinoma, Hepatocellular 46 Squamous Cell Carcinoma of Head and Neck 43 Lung Neoplasms 41 Colorectal Neoplasms 28 Pancreatic Neoplasms 27 Neoplasms 27 Hodgkin Disease 26 Sarcoma 22 Brain Neoplasms 22 Urinary Bladder Neoplasms 20 Stomach Neoplasms 19 Prostatic Neoplasms 19 Breast Neoplasms 19 Head and Neck Neoplasms 18 Glioblastoma 17 Recurrence 16 Colonic Neoplasms 16 Kidney Neoplasms 15 Multiple Myeloma 14 Esophageal Neoplasms 14 Carcinoma, Transitional Cell 14 Small Cell Lung Carcinoma 13 Leukemia, Myeloid, Acute 13 Uveal Melanoma 12 Skin Neoplasms 12 Glioma 12

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡